8-K: Quince Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update, Plans Potential Early Conclusion of Phase 3 NEAT Trial

Quince Therapeutics is considering concluding enrollment early for its Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with its existing cash runway.

Summary

• Quince Therapeutics announced its Q1 2025 financial results and provided a business update on May 13, 2025.
• The company is contemplating an early conclusion of enrollment for its Phase 3 NEAT clinical trial by the end of June 2025.
• This decision aims to align the reporting of topline results with the company's existing cash runway in early 2026.
• As of the report, 63 participants have been enrolled in the NEAT trial, including 56 in the primary analysis population (6-9 years old) and 7 participants aged 10 years or older.
• All 19 study sites are now activated, including sites in the U.K. and Europe.
• The potential early enrollment conclusion by the end of June 2025 would result in approximately 80% power to determine a statistically significant difference in the primary endpoint.
• If additional funding is secured, Quince intends to continue enrollment as previously planned, targeting 86 patients in the primary analysis population.
• The company plans to submit NDA to the FDA and MAA to the EMA in the second half of 2026, assuming positive study results.
• Quince reported cash, cash equivalents, and short-term investments of $31.6 million for the first quarter ended March 31, 2025.
• The company expects its existing cash runway to be sufficient to fund its capital efficient development plan through Phase 3 NEAT topline results, expected by early 2026.
• R&D expenses for Q1 2025 were $8.1 million, primarily related to the Phase 3 NEAT clinical trial.
• G&A expenses for Q1 2025 were $4.8 million, including personnel-related and stock-based compensation expenses.
• The company reported a net loss of $15.0 million, or $0.34 per basic and diluted share, for Q1 2025.
• Net cash used in operating activities was $9.6 million for the first quarter ended March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is facing challenges with enrollment and cash runway, it is taking proactive steps to manage its resources and advance its clinical program. The potential for positive results from the NEAT trial and subsequent regulatory submissions provides some optimism.

Positives

• All 19 study sites for the NEAT trial are now activated, including sites in the U.K. and Europe.
• Approximately seven participants are scheduled for screening over the coming week, suggesting increased screening and randomization activities.
• The NEAT study has a low screen failure rate of 10%.
• All 30 NEAT participants to date have elected to transition to the NEAT open label extension study.
• The company's cash runway is expected to be sufficient to fund the development plan through Phase 3 NEAT topline results.

Negatives

• Quince is contemplating an early conclusion of enrollment for its Phase 3 NEAT clinical trial due to slower than anticipated enrollment and cash runway considerations.
• The company reported a net loss of $15.0 million for Q1 2025.
• Net cash used in operating activities was $9.6 million for the first quarter ended March 31, 2025.

Risks

• Slower than anticipated enrollment in the NEAT trial is impacting the study timeline.
• The company's decision to potentially conclude enrollment early is contingent on securing additional funding.
• The uncertain macroeconomic environment and challenging academic site environment pose risks to the trial.
• The company's plans are dependent on positive results from the NEAT trial and regulatory approval.

Future Outlook

Quince expects its existing cash runway to be sufficient to fund its capital efficient development plan through Phase 3 NEAT topline results, which are now expected by early 2026. Assuming positive results from the NEAT trial, the company plans to submit applications for approval in the U.S. and Europe in the second half of 2026.

Management Comments

• Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, stated that the decision to potentially conclude enrollment of the Phase 3 NEAT clinical trial early is a strategic business decision to maximize a capital efficient development plan.
• Thye noted that the potential to conclude enrollment at the end of June 2025 is expected to provide an approximate 80% power to determine a statistically significant difference in the primary endpoint.

Industry Context

The announcement reflects the challenges faced by biotechnology companies in securing funding and managing clinical trials in an uncertain macroeconomic environment. The focus on capital efficiency and strategic prioritization of clinical programs is a common theme in the current industry landscape.

Comparison to Industry Standards

• The decision to potentially conclude enrollment early to conserve cash is a strategy seen in other biotech companies facing funding constraints, such as Athersys, which restructured its operations to extend its cash runway.
• The reported R&D expenses of $8.1 million are comparable to other small to mid-sized biotech companies in early-stage clinical development, but lower than larger pharmaceutical companies with extensive pipelines.
• The company's cash runway extending through early 2026 is a critical factor for investors, as it provides a timeline for potential value creation through clinical trial results and regulatory submissions.

Stakeholder Impact

• Shareholders may be concerned about the potential early conclusion of enrollment and the need for additional funding.
• Patients with A-T may be impacted by the potential changes to the NEAT trial timeline.
• Employees may be affected by the company's cost-saving measures and strategic prioritization of clinical programs.

Next Steps

• Quince will continue to monitor enrollment in the NEAT trial and make a decision regarding early conclusion of enrollment by the end of June 2025.
• The company will focus on screening and randomization activities at activated study sites.
• Quince will continue to seek additional funding to potentially extend its cash runway and continue enrollment as previously planned.
• Assuming positive study results, the company plans to submit NDA to the FDA and MAA to the EMA in the second half of 2026.

Key Dates

Keywords

Quince Therapeutics, NEAT clinical trial, Ataxia-Telangiectasia, eDSP, Financial results, Enrollment, Phase 3, Cash runway, Rare diseases, Biotechnology